J 2011

Main results of the Ouabain and Adducin for Specific Intervention on Sodium in Hypertension Trial (OASIS-HT): a randomized placebo-controlled phase-2 dose-finding study of rostafuroxin

STAESSEN, Jan, Lutgarde THIJS, Katarzyna STOLARZ-SKRZYPEK, A. BACCHIERI, John BARTON et. al.

Basic information

Original name

Main results of the Ouabain and Adducin for Specific Intervention on Sodium in Hypertension Trial (OASIS-HT): a randomized placebo-controlled phase-2 dose-finding study of rostafuroxin

Authors

STAESSEN, Jan (56 Belgium, guarantor), Lutgarde THIJS (56 Belgium), Katarzyna STOLARZ-SKRZYPEK (616 Poland), A. BACCHIERI (380 Italy), John BARTON (372 Ireland), Ezio ESPOSITI (380 Italy), Peter LEEUW (528 Netherlands), Mirosław DŁUŻNIEWSKI (616 Poland), Nicola GLORIOSO (380 Italy), Andrzej JANUSZEWICZ (616 Poland), Paolo MANUNTA (380 Italy), Viktor MILYAGIN (643 Russian Federation), Yuri NIKITIN (643 Russian Federation), Miroslav SOUČEK (203 Czech Republic, belonging to the institution), Chiara LANZANI (380 Italy), Lorena CITTERIO (380 Italy), Mario TIMIO (380 Italy), Andrzej TYKARSKI (616 Poland), P. FERRARI (380 Italy), G. VALENTINI (380 Italy), K. KAWECKA-JASZCZ (616 Poland) and G. BIANCHI (380 Italy)

Edition

Trials, University of Oxford, 2011, 1745-6215

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30201 Cardiac and Cardiovascular systems

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 2.496

RIV identification code

RIV/00216224:14110/11:00055577

Organization unit

Faculty of Medicine

UT WoS

000286896900001

Keywords in English

Hypertension; sodium; cardiovascular disease

Tags

International impact
Změněno: 20/4/2012 12:29, Mgr. Michal Petr

Abstract

V originále

The Ouabain and Adducin for Specific Intervention on Sodium in Hypertension (OASIS-HT) Trial was a phase-2 dose-finding study of rostafuroxin, a digitoxygenin derivative, which selectively antagonizes the effects of endogenous ouabain (EO) on Na+,K+-ATPase and mutated adducin. Rostafuroxin lowered blood pressure (BP) in some animal models and in humans.